Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 862-867

  Bédos, Jean Pierre ^a   Rieux, Véronique ^a   Bauchet, Jacqueline ^a   Muffat Joly, Martine ^a   Carbon, Claude ^a   Azoulay Dupuis, Esther ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEMAFLOXACIN; TROVAFLOXACIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0344541097     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.862     Document Type: Article

References (34)

1. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:77-83.
2. Appelbaum, P. C. 1996. Emergence of resistance to antimicrobial agents in gram-positive bacteria - pneumococci. Drugs 51(Suppl. 1):1-5.
3. Aubier, M., H. Lode, G. Gialdroni-Grassi, G. Huchon, J. Hosie, N. Legakis, C. Regamey, S. Segev, R. Vester, W. J. Wijnands, and N. Tolstuchow. 1996. Sparfloxacin for the treatment of community acquired pneumonia: a pooled data analysis of two studies. J. Antimicrob. Chemother. 37(Suppl. A):73-82.
4. Azoulay-Dupuis, E., J. P. Bédos, E. Vallée, D. J. Hardy, R. N. Swanson, and J. J. Pocidalo. 1991. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J. Infect. Dis. 163:319-324.
5. Azoulay-Dupuis, E., E. Vallée, B. Veber, J. P. Bédos, J. Bauchet, and J. J. Pocidalo. 1992. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob. Agents Chemother. 36:2698-2703.
6. Azoulay-Dupuis, E., P. Moine, J. P. Bédos, V. Rieux, and E. Vallée. 1996. Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Antimicrob. Agents Chemother. 40:941-946.
7. Bédos, J. P., O. Rollin, D. H. Bouanchaud, and J. J. Pocidalo. 1991. Relation entre virulence et résistance aux antibiotiques des pneumocoques. Pathol. Biol. 39:984-990.
8. Bédos, J. P., E. Azoulay-Dupuis, P. Moine, M. Muffat-Joly, B. Veber, J. J. Pocidalo, and E. Vallée. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model. Relevance for drug efficacy. J. Pharm. Exp. Ther., in press.
9. Briles, D. E., M. J. Crain, B. M. Gray, C. Forman, and J. Yother. 1992. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect. Immun. 60:111-116.
10. Canton, E., J. Peman, M. T. Jimenez, M. S. Ramon, and M. Gobernado. 1992. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob. Agents Chemother. 36:558-565.
11. Carbon, C., P. Leopbonte, P. Peritpretz, J. P. Chauvin, and J. Hazebrouck. 1992. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 36:833-839.
12. Child, J., J. Andrews, F. Boswell, N. Brenwald, and R. Wise. 1995. The in vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Antimicrob. Agents Chemother. 35:869-876.
13. Davis, R., A. Markbam, and J. A. Balfour. 1996. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51: 1019-1074.
14. Edelstein, P. H., M. A. C. Edelstein, J. Ren, R. Polzer, and R. P. Gladue. 1996. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 40:314-319.
15. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering. 1993. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:941-946.
16. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
17. Friedland, I. R., and G. H. McCracken. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med. 331:377-382.
18. Girard, A. E., D. Girard, T. D. Gootz, J. A. Faiella, and C. R. Cimochowski. 1995. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob. Agents Chemother. 39:2210-2216.
19. Gootz, T. D., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697.
20. Hyatt, J. M., D. E. Nix, and J. J. Schentag. 1994. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob. Agents Chemother. 38:2730-2737.
21. Iliadis, A., C. Brown, and M. L. Huggins. 1992. Apis: a software model for identification, simulation and dosage regimen calculation in clinical and experimental pharmacokinetics. Comput. Methods Programs Biomed. 38: 227-239.
22. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1991. Comparative dose-effect relations at several dosing intervals for β-lactam, amino-glycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand. J. Infect. Dis. 74(Suppl.):179-184.
23. Marton, A., M. Gulyas, R. Munoz, and A. Tomasz. 1991. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J. Infect. Dis. 163:542-548.
24. Moreillon, P., Z. Marckiewicz, S. Nachman, and A. Tomasz. 1990. Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms. Antimicrob. Agents Chemother. 34:33-39.
25. National Committee for Clinical Laboratory Standards. 1987. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
26. Neu, H. C., and N. X. Chin. 1994. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob. Agents Chemother. 38:2615-2622.
27. Pallarés, R., J. Linarés, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martin, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
28. e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse.
29. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob. Agents Chemother. 38:2471-2476.
30. Teng, R., S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston. 1995. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Antimicrob. Agents Chemother. 36:385-394.
31. Teng, R., D. Girard, T. D. Gootz, G. Foulds, and T. E. Liston. 1996. Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. Antimicrob. Agents Chemother. 40:561-566.
32. Veber, B., and J. J. Pocidalo. 1995. Le cas particulier des azalides: l'antibiodiapédèse. Données expérimentales à partir d'un modèle murin de pneumonie à pneumocoque. Pathol. Biol. 43:524-528.
33. Vissalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1996. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin, and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. J. Antimicrob. Chemother. 37:77-84.
34. Vogelman, B., S. Gudmunsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.